Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
July 17, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
-- Conference Call Today at 1 PM ET/10 AM PT -- LOS ANGELES, July 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) announced...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
July 15, 2019 06:00 ET
|
Capricor Therapeutics, Inc.
--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled...
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 13, 2019 16:00 ET
|
Capricor Therapeutics, Inc.
On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
May 06, 2019 16:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 15, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
February 06, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients...
FibroGen Reports First Quarter 2018 Financial Results
May 09, 2018 16:02 ET
|
FibroGen, Inc
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018Conference Call Today at 5:00 p.m. Eastern Time/2:00...
Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
February 26, 2018 07:00 ET
|
Summit Therapeutics plc
MRS-T2 Data Provide Evidence of Early Impact of Ezutromid on Downstream Muscle HealthData Build on Positive Biopsy Findings that Showed Significant Decrease in Muscle Damage OXFORD, United Kingdom,...
Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
December 06, 2017 02:00 ET
|
Summit Therapeutics plc
LIESTAL, Switzerland, OXFORD, England and CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Santhera Pharmaceuticals (SIX:SANN), Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), Catabasis...
Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
September 25, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...